Atea Pharmaceuticals (AVIR) Total Liabilities (2019 - 2026)

Atea Pharmaceuticals' Total Liabilities history runs 8 years deep, the most recent figure standing at $267.1 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 824.78% year-over-year to $267.1 million in Q1 2026; TTM through Mar 2026 was $267.1 million, a 824.78% increase from a year earlier, with the FY2025 full-year figure at $39.8 million, up 54.2% from the prior year.
• Total Liabilities advanced to $267.1 million in Q1 2026 per AVIR's latest filing, from $39.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $267.1 million in Q1 2026 and bottomed at $19.9 million in Q1 2023.
• The 5-year median for Total Liabilities is $28.9 million (2025), against an average of $44.8 million.
• Across the five-year window, Total Liabilities tumbled 91.07% in 2022 and jumped 824.78% in 2026, its largest moves.
• Year by year, Total Liabilities stood at $26.1 million in 2022, then surged by 52.19% to $39.8 million in 2023, then tumbled by 35.13% to $25.8 million in 2024, then soared by 54.2% to $39.8 million in 2025, then jumped by 571.32% to $267.1 million in 2026.
• Per Business Quant, the three latest AVIR Total Liabilities figures stand at $267.1 million (Q1 2026), $39.8 million (Q4 2025), and $27.2 million (Q3 2025).